In vitro and in vivo characterization of [64Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors
European Journal of Nuclear Medicine and Molecular Imaging · 2023
DOI: 10.1007/s00259-023-06310-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Tengzhi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physics, Norwegian University of Science and Technology, Trondheim, Norway. Hauptthemen laut MEDLINE: Copper Radioisotopes, Theranostic Nanomedicine, Tumor Hypoxia, Organometallic Compounds. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helse Midt-Norge, Norges Teknisk-Naturvitenskapelige Universitet, St. Olavs Hospital Universitetssykehuset i Trondheim.
Abstract (Originalsprache)
Purpose
Hypoxic tumors are associated with therapy resistance and poor cancer prognosis, but methods to detect and counter tumor hypoxia remain insufficient. Our purpose was to investigate 64 Cu(II)-elesclomol ([ 64 Cu][Cu(ES)]) as a novel theranostic agent for hypoxic tumors, by implementing an improved production method and assessing its therapeutic and diagnostic potential compared to the established Cu-64 radiopharmaceuticals [ 64 Cu]CuCl 2 and [diacetyl-bis(N4-methylthiosemicarbazone) [ 64 Cu][Cu(ATSM)].
Methods
Cu-64 was produced using a biomedical cyclotron at 12 MeV with the reaction 64 Ni(p,n) 64 Cu, followed by synthesis of [ 64 Cu]CuCl 2 , [ 64 Cu][Cu(ATSM)], and [ 64 Cu][Cu(ES)]. In vitro therapeutic effects were assessed in both normoxic and hypoxic cells (22Rv1 and PC3 prostate cancer cells, and U-87MG glioblastoma cells) using the clonogenic assay and analyzing cellular uptake and internalization. In vivo therapeutic effects were assessed in 22Rv1 xenografts in BALB/cAnN-Foxn1nu/nu/Rj mice receiving a single or multiple doses of radiopharmaceutical, before their feasibility to detect tumor hypoxia was assessed by positron emission tomography (PET) in 22Rv1 and U-87MG xenografts.
Results
In vitro and in vivo studies demonstrated that [ 64 Cu][Cu(ES)] reduced cell survival and inhibited tumor growth more effectively than [ 64 Cu][Cu(ATSM)] and [ 64 Cu]CuCl 2 . Hypoxia increased the cellular uptake and internalization of [ 64 Cu][Cu(ES)] and [ 64 Cu][Cu(ATSM)]. [ 64 Cu][Cu(ES)]-PET tumor hypoxia detection was feasible and also revealed an unexpected finding of uptake in the brain.
Conclusion
To the best of our knowledge, this is the first time that ES is radiolabeled with [ 64 Cu]CuCl 2 to [ 64 Cu][Cu(ES)]. We demonstrated superior therapeutic effects of [ 64 Cu][Cu(ES)] compared to [ 64 Cu][Cu(ATSM)] and [ 64 Cu]CuCl 2 and that [ 64 Cu][Cu(ES)]-PET is feasible. [ 64 Cu][Cu(ES)] is a promising theranostic agent for hypoxic solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physics, Norwegian University of Science and Technology, Trondheim, Norway.
- Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
- Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity St. James's Cancer Institute, Trinity College, Dublin, Ireland.
- Department of Physics, Norwegian University of Science and Technology, Trondheim, Norway. kathrine.redalen@ntnu.no.
ORCID-Profile: Tengzhi Liu, Maria Aanesland Dahle, Mathilde Hirsum Lystad, Laure Marignol, Morten Karlsen, Kathrine Røe Redalen
Förderung
- Helse Midt-Norge
- Norges Teknisk-Naturvitenskapelige Universitet
- St. Olavs Hospital Universitetssykehuset i Trondheim
- NTNU Norwegian University of Science and Technology
Zitieren
APA
Liu, T., Dahle, M. A., Lystad, M. H., Marignol, L., Karlsen, M., & Redalen, K. R. (2023). In vitro and in vivo characterization of [64Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06310-4
Vancouver
Liu T, Dahle MA, Lystad MH, Marignol L, Karlsen M, Redalen KR. In vitro and in vivo characterization of [64Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06310-4
BibTeX
@article{Liu2023,
author = {Liu, Tengzhi and Dahle, Maria Aanesland and Lystad, Mathilde Hirsum and Marignol, Laure and Karlsen, Morten and Redalen, Kathrine Røe},
title = {In vitro and in vivo characterization of [64Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
doi = {10.1007/s00259-023-06310-4}
}
EUVIMED